Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial
Phase of Trial: Phase IV
Latest Information Update: 02 Jul 2018
At a glance
- Drugs Empagliflozin (Primary) ; Sitagliptin
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms ELITE
- 21 Jun 2018 Planned End Date changed from 30 Jun 2020 to 30 Apr 2021.
- 21 Jun 2018 Planned primary completion date changed from 31 Dec 2019 to 30 Sep 2020.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.